In 2018, a clinical study revealed an ORR of 90.0% and an intracranial ORR of 66.7% in naïve NSCLC patients treated with lorlatinib, whereas 198 patients previously treated with ALK inhibitors showed an ORR of 47.0% and an intracranial ORR of 63.0%. The gene discussed is ALK; the disease is non-small cell lung carcinoma.